Clinical Trial Update: Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Myocet (doxorubicin liposome) plus carboplatin in relapsed, platinum-sensitive ovarian cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Myocet (liposomal doxorubicin)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED